Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ERIC 2018 | Resistance mechanisms in CLL

Richard Rosenquist • 25 Oct 2018
ERIC 2018
Chronic Lymphocytic Leukemia Leukemia

Relapsed chronic lymphocytic leukemia (CLL) patients exhibit unforeseen aberrations in ribosomal genes, says Richard Rosenquist, MD, PhD, of the Karolinska University Hospital, Solna, Sweden. Prof. Rosenquist further expresses his hope of understanding resistance mechanisms in CLL using next-generation sequencing, at the European Research Initiative on CLL (ERIC) International Meeting 2018, held in Barcelona, Spain.

More from Richard Rosenquist

1:50
The impact of IGHV mutational status in treatment decisions in CLL
Richard Rosenquist • 7 Oct 2022
1:26
Common genetic tests in CLL & when these tests should be performed
Richard Rosenquist • 7 Oct 2022
1:31
Using genomics to better understand the pathogenesis of CLL & for early disease diagnosis
Richard Rosenquist • 7 Oct 2022
1:38
The importance of TP53 in CLL
Richard Rosenquist • 7 Oct 2022

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals